Condition: Advanced Solid Tumors · Sponsor: CStone Pharmaceuticals
This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy in Participants with Advanced Solid Tumors. The study is comprised of a Phase I dose escalation and Phase II dose expansion.
This description comes directly from the study's public registry record.
Jingru Wang · +86 18017113282 · wangjingru@cstonepharma.com
Always discuss trial participation with your own doctor first.
| START Los Angeles, LLC | Los Angeles, California, United States | Recruiting |
| NEXT Dallas | Irving, Texas, United States | Recruiting |
| Alfred Hospital (Alfred Health) | Melbourne, Australia | Recruiting |
| Austin Hospital (Austin Health) | Melbourne, Australia | Recruiting |
| Monash Medical Centre (Monash Health) | Melbourne, Australia | Recruiting |
| Peter Maccallum Cancer Centre Research | Melbourne, Australia | Recruiting |
| Icon Cancer Centre South Brisbane | South Brisbane, Australia | Recruiting |
| Blacktown Hospital | Sydney, Australia | Recruiting |
| Macquarie University Hospital | Sydney, Australia | Recruiting |
| Scientia Clinical Research Ltd | Sydney, Australia | Recruiting |
| Beijing Cancer Hospital | Beijing, China | Recruiting |
| Jilin Cancer Hospital | Changchun, China | Recruiting |
+ 21 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06741644